Clinical Trials

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05166616 2026-03-05

Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

8 enrolled

Lung Neoplasms

NCT03392246 2026-01-22

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04743505 2026-01-20

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

27 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05089916 2026-01-14

ROSE

42 enrolled

NSCLC

NCT04769388 2026-01-12

FLAME

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03410043 2025-12-26

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

173 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05017025 2025-11-19

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

32 enrolled

Lung Neoplasms

NCT03122717 2025-11-12

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03667820 2025-11-04

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

41 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03909334 2025-10-20

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

160 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04695925 2025-10-15

TOP

294 enrolled

Non-small Cell Carcinoma

NCT05773092 2025-09-03

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

Phase 1 Active not recruiting

NSCLC

NCT03567642 2025-07-03

A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

11 enrolled

Lung Neoplasms

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

423 enrolled

Phase NA Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03969823 2025-05-15

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

148 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04141644 2025-04-16

Osi+Ipi

24 enrolled

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)

NCT06827145 2025-02-14

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

NCT03433469 2025-01-31

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

27 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03769103 2024-10-31

Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

40 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04545710 2024-08-05

Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

18 enrolled

Lung Neoplasms

NCT03804580 2024-05-07

FIOL

100 enrolled

Lung Neoplasms

NCT05163249 2024-02-09

FLOWERS

44 enrolled